# Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

Study · id `cardio:ct-nct03061214` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03061214](<https://clinicaltrials.gov/study/NCT03061214>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03061214

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 868 participants.

## Technical summary

Registry record NCT03061214. Randomized; double masking; primary purpose treatment. Start 2017-08-28 (actual); primary completion 2019-03-14 (actual). Results posted on 2020-04-09.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 868 participants (enrolled count; ClinicalTrials.gov record NCT03061214, source copy `cardio:ctgov-nct03061214-2021-03-02`, retrieved 2026-10-26)
- Started: 2017-08-28 (actual) (ClinicalTrials.gov record NCT03061214, source copy `cardio:ctgov-nct03061214-2021-03-02`, retrieved 2026-10-26)
- Primary completion: 2019-03-14 (actual) (ClinicalTrials.gov record NCT03061214, source copy `cardio:ctgov-nct03061214-2021-03-02`, retrieved 2026-10-26)
- Completion: 2019-04-15 (actual) (ClinicalTrials.gov record NCT03061214, source copy `cardio:ctgov-nct03061214-2021-03-02`, retrieved 2026-10-26)
- Results first posted: 2020-04-09 (ClinicalTrials.gov record NCT03061214, source copy `cardio:ctgov-nct03061214-2021-03-02`, retrieved 2026-10-26)
- Countries: Brazil; China; Hong Kong SAR China; South Africa; South Korea; Taiwan; Ukraine (ClinicalTrials.gov record NCT03061214, source copy `cardio:ctgov-nct03061214-2021-03-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03061214-2021-03-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
- Acronym: SUSTAIN
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide 0.5 mg
- Intervention (Drug): Semaglutide 1.0 mg
- Intervention (Drug): Sitagliptin placebo
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Semaglutide placebo 0.5 mg
- Intervention (Drug): Semaglutide placebo 1.0 mg
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial (`cardio:pubmed-33074557`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1906b8345a71ab671bce60fd330daa2fe211349b3bdbc8880808389442c2cd0a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
